Previous presentation: This work was presented at the 2018 ASCO Annual Meeting; June 1–5, 2018; Chicago, Illinois.
Author contributions: Study concept: Kommalapati, Tella. Study design: Kommalapati, Tella, Appiah, Ganti. Data acquisition: Kommalapati, Tella. Data interpretation: Tella, Appiah, Smith. Manuscript preparation: Kommalapati, Tella, Ganti. Critical revision: All authors. Final manuscript approval: All authors.
Disclosures: The authors have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.
American Cancer Society. Cancer Facts and Figures 2018. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf. Accessed March 1 2018.
Biswas TSharma NMachtay M. Controversies in the management of stage III non-small-cell lung cancer. Expert Rev Anticancer Ther 2014;14:333–347.
Patel APCrabtree TDBell JM. National patterns of care and outcomes after combined modality therapy for stage IIIA non-small-cell lung cancer. J Thorac Oncol 2014;9:612–621.
Berry MFWorni MPietrobon R. Variability in the treatment of elderly patients with stage IIIA (N2) non-small cell lung cancer. J Thorac Oncol 2013;8:744–752.
Albain KSSwann RSRusch VW. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374:379–386.
Kumar SSHiggins KAMcGarry RC. Emerging therapies for stage III non-small cell lung cancer: stereotactic body radiation therapy and immunotherapy. Front Oncol 2017;7:197.
Santana-Davila RMartins R. Treatment of stage IIIA non-small-cell lung cancer: a concise review for the practicing oncologist. J Oncol Pract 2016;12:601–606.
Bach PBCramer LDSchrag D. The influence of hospital volume on survival after resection for lung cancer. N Engl J Med 2001;345:181–188.
Farjah FFlum DRVarghese TK Jr. Surgeon specialty and long-term survival after pulmonary resection for lung cancer. Ann Thorac Surg 2009;87:995–1004 discussion 1005–1006.
Van Schil PE. Stage IIIA-N2 non-small-cell lung cancer: from ‘surprise’ involvement to surgical nightmare. Eur J Cardiothorac Surg 2016;49:1613–1614.
Eaton BRPugh SLBradley JD. Institutional enrollment and survival among NSCLC patients receiving chemoradiation: NRG Oncology Radiation Therapy Oncology Group (RTOG) 0617. J Natl Cancer Inst 2016;108:djw034.
Myrdal GGustafsson GLambe M. Outcome after lung cancer surgery. Factors predicting early mortality and major morbidity. Eur J Cardiothorac Surg 2001;20:694–699.
Shi WZhang WSun H. Sleeve lobectomy versus pneumonectomy for non-small cell lung cancer: a meta-analysis. World J Surg Oncol 2012;10:265.
Lee ESPark SIKim YH. Comparison of operative mortality and complications between bronchoplastic lobectomy and pneumonectomy in lung cancer patients. J Korean Med Sci 2007;22:43–47.
Camposilvan IAkhtar-Danesh NSchneider L. The effect of surgeon volume on procedure selection in non–small cell lung cancer surgeries. J Thorac Cardiovasc Surg 2015;150:507–513.
Finks JFOsborne NHBirkmeyer JD. Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med 2011;364:2128–2137.
Wang EHRutter CECorso CD. Patients selected for definitive concurrent chemoradiation at high-volume facilities achieve improved survival in stage III non-small-cell lung cancer. J Thorac Oncol 2015;10:937–943.